Non-small cell lung cancer · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | standard |
|---|---|
| Linked regimen | None |
| ID | IND-IATROGENIC-BLEOMYCIN-LATE-PREVENTION-SURVEILLANCE |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-COG SRC-NCCN-BCELL-2025 SRC-NCCN-NSCLC-2025 |
Notes
STUB — cancer-survivor late-effects pilot (bleomycin pulmonary). Three surveillance domains: pulmonary fibrosis (PFTs), second-primary lung cancer (LDCT eligibility shift), lifelong high-FiO2 caution. Two-Clinical-Co-Lead signoff queued.
Used By
No reverse references found in the YAML corpus.